Corporate Tech Investors

Innoviva

Innoviva is a corporate VC investing group that invests in companies that are a good strategic fit.

Venture Investor Overview

Contact Information

Background Information

Overview

Innoviva, Inc. is a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

3/4/2024

Transaction History

Our records indicate that Innoviva invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Chief Executive Officer

Pavel Raifeld

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

Innoviva has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Browse more corporate investors:

Innovius | INO

Share this article

About Our Corporate VC Database

This corporate tech investor profile is powered by VentureDeal.com, a market leader in strategic investor transaction data for corporations that invest in the tech sector.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary